Literature DB >> 34773460

Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.

Nicholas A Marston1, Robert P Giugliano1, Giorgio E M Melloni1, Jeong-Gun Park1, Valerie Morrill2, Michael A Blazing3, Brian Ference4, Evan Stein5, Erik S Stroes6, Eugene Braunwald1, Patrick T Ellinor2,7,8, Steven A Lubitz2,7,8, Christian T Ruff1, Marc S Sabatine1.   

Abstract

IMPORTANCE: Lipid management typically focuses on levels of low-density lipoprotein cholesterol (LDL-C) and, to a lesser extent, triglycerides (TG). However, animal models and genetic studies suggest that the atherogenic particle subpopulations (LDL and very-low-density lipoprotein [VLDL]) are both important and that the number of particles is more predictive of cardiac events than their lipid content.
OBJECTIVE: To determine whether common measures of cholesterol concentration, TG concentration, or their ratio are associated with cardiovascular risk beyond the number of apolipoprotein B (apoB)-containing lipoproteins. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort analysis included individuals from the population-based UK Biobank and from 2 large international clinical trials, FOURIER and IMPROVE-IT. The median (IQR) follow-up was 11.1 (10.4-11.8) years in UK Biobank and 2.5 (2.0-4.7) years in the clinical trials. Two populations were studied in this analysis: 389 529 individuals in the primary prevention group who were not taking lipid-lowering therapy and 40 430 patients with established atherosclerosis who were receiving statin treatment. EXPOSURES: ApoB, non-high-density lipoprotein cholesterol (HDL-C), LDL-C, and TG. MAIN OUTCOME AND MEASURES: The primary study outcome was incident myocardial infarction (MI).
RESULTS: Of the 389 529 individuals in the primary prevention group, 224 097 (58%) were female, and the median (IQR) age was 56.0 (49.5-62.5) years. Of the 40 430 patients with established atherosclerosis, 9647 (24%) were female, and the median (IQR) age was 63 (56.2-69.0) years. In the primary prevention cohort, apoB, non-HDL-C, and TG each individually were associated with incident MI. However, when assessed together, only apoB was associated (adjusted hazard ratio [aHR] per 1 SD, 1.27; 95% CI, 1.15-1.40; P < .001). Similarly, only apoB was associated with MI in the secondary prevention cohort. Adjusting for apoB, there was no association between the ratio of TG to LDL-C (a surrogate for the ratio of TG-rich lipoproteins to LDL) and risk of MI, implying that for a given concentration of apoB-containing lipoproteins, the relative proportions of particle subpopulations may no longer be a predictor of risk. CONCLUSIONS AND RELEVANCE: In this cohort study, risk of MI was best captured by the number of apoB-containing lipoproteins, independent from lipid content (cholesterol or TG) or type of lipoprotein (LDL or TG-rich). This suggests that apoB may be the primary driver of atherosclerosis and that lowering the concentration of all apoB-containing lipoproteins should be the focus of therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34773460      PMCID: PMC8590731          DOI: 10.1001/jamacardio.2021.5083

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  22 in total

1.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

2.  Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.

Authors:  Camilla Ditlev Lindhardt Johannesen; Martin Bødtker Mortensen; Anne Langsted; Børge Grønne Nordestgaard
Journal:  J Am Coll Cardiol       Date:  2021-03-23       Impact factor: 24.094

3.  Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease.

Authors:  Olga Castañer; Xavier Pintó; Isaac Subirana; Antonio J Amor; Emilio Ros; Álvaro Hernáez; Miguel Ángel Martínez-González; Dolores Corella; Jordi Salas-Salvadó; Ramón Estruch; José Lapetra; Enrique Gómez-Gracia; Angel M Alonso-Gomez; Miquel Fiol; Lluís Serra-Majem; Emili Corbella; David Benaiges; Jose V Sorli; Miguel Ruiz-Canela; Nancy Babió; Lucas Tojal Sierra; Emilio Ortega; Montserrat Fitó
Journal:  J Am Coll Cardiol       Date:  2020-12-08       Impact factor: 24.094

4.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

5.  Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices.

Authors:  Thomas G Cole; John H Contois; Gyorgy Csako; Joseph P McConnell; Alan T Remaley; Sridevi Devaraj; Daniel M Hoefner; Tonya Mallory; Amar A Sethi; G Russell Warnick
Journal:  Clin Chem       Date:  2013-02-05       Impact factor: 8.327

6.  The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine.

Authors:  Paul Elliott; Tim C Peakman
Journal:  Int J Epidemiol       Date:  2008-04       Impact factor: 7.196

7.  Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.

Authors:  Samia Mora; James D Otvos; Nader Rifai; Robert S Rosenson; Julie E Buring; Paul M Ridker
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

8.  Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events.

Authors:  Samia Mora; Julie E Buring; Paul M Ridker
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

9.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Authors:  François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983

10.  The UK Biobank resource with deep phenotyping and genomic data.

Authors:  Clare Bycroft; Colin Freeman; Desislava Petkova; Gavin Band; Lloyd T Elliott; Kevin Sharp; Allan Motyer; Damjan Vukcevic; Olivier Delaneau; Jared O'Connell; Adrian Cortes; Samantha Welsh; Alan Young; Mark Effingham; Gil McVean; Stephen Leslie; Naomi Allen; Peter Donnelly; Jonathan Marchini
Journal:  Nature       Date:  2018-10-10       Impact factor: 49.962

View more
  6 in total

1.  Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.

Authors:  Brian A Bergmark; Nicholas A Marston; Marc S Sabatine; Stephen D Wiviott; Candace R Bramson; Madelyn Curto; Vesper Ramos; Alexandra Jevne; Julia F Kuder; Jeong-Gun Park; Sabina A Murphy; Subodh Verma; Wojtek Wojakowski; Steven G Terra
Journal:  Circulation       Date:  2022-04-03       Impact factor: 39.918

Review 2.  Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).

Authors:  Jih-Kai Huang; Hsiang-Chun Lee
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

3.  Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a).

Authors:  Anindita Chakraborty; Dick C Chan; Katrina L Ellis; Jing Pang; Wendy Barnett; Ann Marie Woodward; Mary Vorster; Richard Norman; Eric K Moses; Gerald F Watts
Journal:  Am J Prev Cardiol       Date:  2022-04-21

4.  Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol.

Authors:  Maureen Sampson; Anna Wolska; Jeff W Meeusen; Leslie J Donato; Allan S Jaffe; Alan T Remaley
Journal:  Front Genet       Date:  2022-07-14       Impact factor: 4.772

Review 5.  Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.

Authors:  Adam J Nelson; Allan D Sniderman; Marc Ditmarsch; Mary R Dicklin; Stephen J Nicholls; Michael H Davidson; John J P Kastelein
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208

6.  Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Authors:  Emil Hagström; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Nicolas Danchin; Rafael Diaz; Shaun G Goodman; Robert A Harrington; J Wouter Jukema; Evangelos Liberopoulos; Nikolaus Marx; Jennifer McGinniss; Garen Manvelian; Robert Pordy; Michel Scemama; Harvey D White; Andreas M Zeiher; Gregory G Schwartz
Journal:  Circulation       Date:  2022-06-30       Impact factor: 39.918

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.